GANNON STEVEN 4
4 · Xenon Pharmaceuticals Inc. · Filed Jun 6, 2025
Insider Transaction Report
Form 4
GANNON STEVEN
Director
Transactions
- Sale
Common Shares
2025-06-05$30.48/sh−3$91→ 7,141 total - Award
Share Option (Right to Buy)
2025-06-05+17,012→ 17,012 totalExercise: $30.73Exp: 2035-06-04→ Common Shares (17,012 underlying) - Award
Restricted Share Units
2025-06-05+2,645→ 2,645 totalExercise: $0.00→ Common Shares (2,645 underlying)
Footnotes (3)
- [F1]Shares automatically sold in payment of transfer fee for transfer of shares to an alternate brokerage account.
- [F2]Vesting 100% on the earlier of (i) June 4, 2026 or (ii) the day before the date of the issuer's 2026 annual meeting of shareholders.
- [F3]Each restricted share unit represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 4, 2026 or (ii) the day before the date of the issuer's 2026 annual meeting of shareholders.